| Ribosomal multilocus sequence typing: universal characterization of bacteria from domain to strain KA Jolley, CM Bliss, JS Bennett, HB Bratcher, C Brehony, FM Colles, ... Microbiology 158 (4), 1005-1015, 2012 | 581 | 2012 |
| Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species S Colloca, E Barnes, A Folgori, V Ammendola, S Capone, A Cirillo, ... Science translational medicine 4 (115), 115ra2-115ra2, 2012 | 337 | 2012 |
| A monovalent chimpanzee adenovirus Ebola vaccine boosted with MVA K Ewer, T Rampling, N Venkatraman, G Bowyer, D Wright, T Lambe, ... New England Journal of Medicine 374 (17), 1635-1646, 2016 | 299 | 2016 |
| ChAd63-MVA–vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans SH Sheehy, CJA Duncan, SC Elias, P Choudhary, S Biswas, FD Halstead, ... Molecular Therapy 20 (12), 2355-2368, 2012 | 246 | 2012 |
| A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial R Nachbagauer, J Feser, A Naficy, DI Bernstein, J Guptill, EB Walter, ... Nature medicine 27 (1), 106-114, 2021 | 243 | 2021 |
| A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice AW Freyn, JR da Silva, VC Rosado, CM Bliss, M Pine, BL Mui, YK Tam, ... Molecular Therapy 28 (7), 1569-1584, 2020 | 203 | 2020 |
| Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults C Ogwang, D Kimani, NJ Edwards, R Roberts, J Mwacharo, G Bowyer, ... Science translational medicine 7 (286), 286re5-286re5, 2015 | 160 | 2015 |
| Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals SH Hodgson, KJ Ewer, CM Bliss, NJ Edwards, T Rampling, ... The Journal of infectious diseases 211 (7), 1076-1086, 2015 | 155 | 2015 |
| A monovalent chimpanzee adenovirus Ebola vaccine—preliminary report T Rampling, K Ewer, G Bowyer, D Wright, E Imoukhuede, R Payne, ... New England Journal of Medicine, 2015 | 138 | 2015 |
| Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME … C Ogwang, M Afolabi, D Kimani, YJ Jagne, SH Sheehy, CM Bliss, ... PloS one 8 (3), e57726, 2013 | 98 | 2013 |
| Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara … T Rampling, KJ Ewer, G Bowyer, CM Bliss, NJ Edwards, D Wright, ... The Journal of infectious diseases 214 (5), 772-781, 2016 | 86 | 2016 |
| First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children AB Tiono, I Nébié, N Anagnostou, AS Coulibaly, G Bowyer, E Lam, ... PloS one 13 (12), e0208328, 2018 | 77 | 2018 |
| Safety and immunogenicity of ChAd63 and MVA ME-TRAP in West African children and infants MO Afolabi, AB Tiono, UJ Adetifa, JB Yaro, A Drammeh, I Nébié, C Bliss, ... Molecular Therapy 24 (8), 1470-1477, 2016 | 71 | 2016 |
| Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure S Biswas, P Choudhary, SC Elias, K Miura, KH Milne, SC de Cassan, ... PloS one 9 (9), e107903, 2014 | 71 | 2014 |
| Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations D Kimani, YJ Jagne, M Cox, E Kimani, CM Bliss, E Gitau, C Ogwang, ... Molecular Therapy 22 (11), 1992-2003, 2014 | 70 | 2014 |
| Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in … VA Mensah, A Gueye, M Ndiaye, NJ Edwards, D Wright, NA Anagnostou, ... PLoS One 11 (12), e0167951, 2016 | 61 | 2016 |
| A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS E De Barra, SH Hodgson, KJ Ewer, CM Bliss, K Hennigan, A Collins, ... PloS one 9 (12), e115161, 2014 | 60 | 2014 |
| Safety and efficacy of novel malaria vaccine regimens of RTS, S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP T Rampling, KJ Ewer, G Bowyer, NJ Edwards, D Wright, S Sridhar, ... NPJ vaccines 3 (1), 49, 2018 | 55 | 2018 |
| Viral vector malaria vaccines induce high-level T cell and antibody responses in West African children and infants CM Bliss, A Drammeh, G Bowyer, GS Sanou, YJ Jagne, O Ouedraogo, ... Molecular Therapy 25 (2), 547-559, 2017 | 53 | 2017 |
| Analysis of human B‐cell responses following C h A d63‐MVA MSP 1 and AMA 1 immunization and controlled malaria infection SC Elias, P Choudhary, SC de Cassan, S Biswas, KA Collins, ... Immunology 141 (4), 628-644, 2014 | 51 | 2014 |
